consumer genomics
23andMe Gains FDA Clearance for Direct-to-Consumer Prostate Cancer Genetic Risk Test
The firm is now authorized to sell a genetic health report on the HOXB13 marker that indicates risk for hereditary prostate cancer, its third DTC cancer risk report with 510(k) clearance.
Called Personal Access to Genome and Analysis of Natural Traits, or PAGEANT, the platform enables users to analyze and interpret their genomic data at no cost.
With $8 million in new funding, the startup is expanding beyond its DTC roots by offering "legit science" to support its personalized health recommendations.
23andMe Fiscal Q2 Revenues Increase 7 Percent
The consumer genetic testing company logged $55.2 million in revenues primarily due to higher sales of its Personal Genome Service kit and subscriptions.
The consumer genetic testing giant sees the $400 million deal as a catalyst for personalized healthcare.